INTRODUCTION
Passenger B lymphocyte syndrome (PBLS) has been described after hematopoietic progenitors and solid organ transplantation 1,2 and may occur when there is a minor erythrocyte antigen mismatch between donor and recipient. It is mediated by graft B lymphocytes that recognize erythrocyte antigens as non-self with subsequent alloimmune response causing hemolytic anemia, through the production of antibodies against recipient red cell antigens. PBLS incidence in kidney transplantation (KT) varies between 9 and 20% according to publications [1] [2] [3] . It is predominantly mediated by ABO isoagglutinins and rarely by Rh antibodies. A Coombs positive anemia 7-14 days after a transplant with minor blood antigens incompatibility should raise diagnostic suspicion for this entity 2 . A correct and prompt management is essential to ensure a good outcome.
CASE REPORT
A fifty-three-year-old woman with end stage renal disease secondary to IgA nephropathy was admitted for donor living KT in July 2018.
She was on peritoneal dialysis (PD) since August 2014 and was submitted to living donor KT from her sister in October 2014.
The patient was O Rh positive (ccDEe) and had negative indirect antiglobulin test (IAT) and negative direct antiglobulin test (DAT); Her HLA low resolution typing was: A (2, 32); B (65, 63); DR 1, 13 . Her sister was O Rh positive; HLA low resolution typing: A (1, 32); B (8, 14) ; DR (1, 8) . Complement dependent cytotoxicity (CDC) and flow cytometry cross match were negative, panel reactive antibody (PRA) was 0%. This first transplantation surgery was complicated by immediate graft arterial thrombosis and graft nephrectomy was needed at day (D) 1, with patient returning to PD. A thrombophilia study did not detect any mutation in prothrombin gene and FV Leiden. Circulating phospholipid antibodies as well as ATIII, protein C and protein S deficiencies were excluded.
Her present donor was a fifty-three -year-old female friend. Her blood group was O Rh negative (ccdee). In her obstetric anamnesis, she referred an Rh immunizing event during a 1 st pregnancy in 2005 and occurrence of foetal haemolytic disease mediated by anti-Rh (D) during her 2 nd pregnancy in 2011, with need for cesarean delivery at 32 week of gestation.
Her low-resolution HLA typing was: A (2); B (44, 51); DR (7, 18) . Complement dependent cytotoxicity (CDC) and flow cytometry cross match were negative; panel reactive antibody (PRA) was 0%. A nondonor specific low title anti-HLA A1 was detected.
Her immunosuppression protocol included Basiliximab, tacrolimus, mycophenolate mofetil and corticoids.
The surgical procedure was complicated with thrombosis of proximal iliac artery and an urgent thrombectomy was performed at D1, followed by a haemorrhagic shock. At D2 Balloon angioplasty was done but after rupture of the heterologous graft renal artery a surgical bypass with interposition of large saphenous vein was required.
She had delayed graft function, remaining on haemodialysis for 4 days. Given this complicated immediate post-KT period, adequate tacrolimus trough levels were not achieved and clinicians opted for changing induction strategy, starting anti-thymocyte globulin (ATG) at D3 that was administered for 7 consecutive days. She was also treated with polyvalent human immunoglobulin (0.5 g/kg/day x 3 days) and methylprednisolone (625 mg x 3 days). Immunohematology clinical evolution is shown in Table I .
On D44 she reached clinical and analytical stability (creatinine 0.9 mg/dl, Hb 9.0 g/dl, reticulocyte count 152 x 10 9 /L, DHL 279 U/L and indirect bilirubin 0.78 mg/dl) and was discharged. DAT+ Hemolytic anemia persisted for over 3 months with hemoglobin values between 7.3 g/dl and 10.2 g/dl (Table I) , reticulocytosis and slightly elevated DHL and indirect bilirubin. Six months after KT the patient had hemoglobin 12.2 g/dl but maintained a positive IAT with an anti-D title 1:2.
DISCUSSION
The role of donor tissue-resident lymphocytes subsets has increasingly been studied in solid organ transplantation. Donor lymphocytes, in particular donor derived tissue resident T regulatory (Treg) cells, seem to be required for tolerance induction, as evidenced by the fact that irradiation of donor graft in rodent models led to rejection of otherwise tolerated transplants 4 .
Additionally, donor derived tissue resident T cells might also protect against infection 4 .
However, donor memory CD4+ T cells and donor passenger B lymphocytes may be implicated in moderate to severe immune complications after solid organ transplantation. Several cases of PBLS in the context of renal transplantation have been described, mainly related to minor ABO incompatibility 3, 5, 6 . PBLS due to Rh incompatibility is rarer, with only 10 reported cases to our knowledge (Table II) 3, 7 .
The severity of the hemolytic condition is variable and may be related to the conditioning regimen, to the amount of lymphocytes transferred with the engraft as well as to the type of implicated immunoglobulin 3 .
Immune hemolytic anemia starts within 7-14 days and usually selflimits within 6 to 8 weeks after transplantation. However, cases in which the hemolytic condition lasted up to 6 months 8 have been described.
In the presented case the appearance of a hemolytic anemia raised some diagnostic hypotheses namely the possibility of a posttransplant thrombotic microangiopathy or an immune-mediated 11 Pos IgG ---frohn et al. 12 Pos IgG 14 14 13 pomper et al. 13 Pos IgG 13 -16 karanth et al. 7 Pos IgG, C3d and IgM 15 -4 hemolytic anemia associated to immunosuppressive drugs as tacrolimus or ATG.
As rhesus (Rh) antigens are not expressed on kidney tissue cell surfaces, matching for Rh antigens is not relevant in most settings but the possible occurrence of an Rh associated PBLS should have been kept in mind.
Transfusion with donor-type RBC is recommended in these cases until the TAD gets negative.
The patient had several postoperative complications demanding 2 surgical re-interventions and the need of multiple transfusions. Hence, Rh positive RBCs increased immune stimulation and an exuberant anamnestic response by the donor memory B lymphocytes, leading to a severe hemolytic anemia. At that time, the presence of high title anti-D was documented and confirmed the diagnosis of PBLS. Afterwards an appropriate transfusion protocol with Rh negative RBCs was established but the hemolytic condition persisted for over 3 months.
The factors that contributed to the clinical severity in this case were the presence of previous sensitization and alloimmunization in the donor and the need for multiple transfusions in the recipient in the first 2 weeks after transplantation. We question whether it wouldn't be opportune to transfuse these patients with Rh negative RBC since the day of surgery, regardless of the DAT result, as recommended in hematopoietic stem cell transplantation.
Besides transfusion with donor-type RBC, other therapeutics are available in PBLS namely steroids, plasmapheresis and rituximab 2, 3 .
Rituximab is an anti-CD20 monoclonal antibody and its role in preventing PBLS has been well documented in allogenic stem cell transplantation.
A recent paper from Tsujimura and colleagues 14 evaluated the efficacy of rituximab in preventing PBLS in 85 patients treated with ABO mismatched KT during a period of 8 years. None of the patients treated with rituximab had PBLS so the monoclonal antibody seems to be efficacious in inhibiting B lymphocytes proliferation.
The present case points out that PBLS should be considered in the presence of Rh incompatibility in the donor/recipient pair when DAT+ hemolytic anemia occurs. It is a potentially serious clinical condition and requires a prompt diagnosis and treatment, being particularly important the transfusion management with Rh negative RBCs.
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